Table 2.

Kaplan-Meier estimates using log-rank test for overall survival in relation to IHC, intratumoral heterogeneity and clinicopathologic indicators.

Univariate regression analysis				Intratumoral heterogeneity indicators
	HR	95% CI	p-value		HR	95% CI	p-value
Conventional breast cancer indicators
ER%	3.11	1.16–8.34	0.017	ER_energy	4.56	1.36–15.31	0.007
PR%	0.30	0.14–0.68	0.002	ER_homogeneity	3.40	1.52–7.62	0.002
Ki67%	2.13	0.80–5.71	0.120	ER_entropy	0.09	0.01–0.68	0.003
HER2%	0.39	0.17–0.92	0.025	ER_contrast	0.31	0.14–0.71	0.004
Immune response indicators				ER_dissimilarity	0.32	0.14–0.70	0.003
CD8_d_S	0.31	0.11–0.82	0.013	ER_AshD	2.11	0.72–6.17	0.160
CD8_d_T	0.23	0.10–0.57	0.0005	PR_energy	5.36	2.12–13.52	<0.0001
CD8_SATB1_d_S	0.32	0.13–0.81	0.011	PR_homogeneity	4.88	2.02–11.79	0.0001
CD8_SATB1_d_T	0.26	0.11–0.57	0.0004	PR_entropy	0.21	0.08–0.52	0.0002
Hypoxia-inducible indicators				PR_contrast	0.22	0.09–0.56	0.0005
HIF1α%_S	0.43	0.15–1.26	0.11	PR_dissimilarity	0.15	0.05–0.44	<0.0001
HIF1α%_T	0.46	0.16–1.35	0.15	PR_AshD	0.32	0.14–0.71	0.003
Clinicopathological variables				Ki67_energy	0.48	0.20–1.17	0.100
G stage (G1–2 vs. G3)	1.20	0.52–2.81	0.670	Ki67_homogeneity	0.46	0.19–1.12	0.079
T stage (T1 vs. T2)	0.99	0.45–2.22	0.986	Ki67_entropy	2.06	0.85–4.98	0.100
N status (N0 vs. N1–3)	2.17	0.95–4.97	0.07	Ki67_contrast	2.11	0.93–4.74	0.066
Age (≤ 59 vs. > 59)	2.45	1.05–5.73	0.039	Ki67_dissimilarity	2.16	0.89–5.21	0.079
–	–	–	–	Ki67_AshD	2.48	1.09–5.68	0.026

AshD, Ashman's D; d, density; S, stroma compartment; T, tumor compartment; HR, hazard ratio; CI, confidence interval.